Tuija Tapaninen

Dr. Tuija Tapaninen

orcid

Research Focus & Metrics

Academic Career Length

17Years (2010-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
27 June 2014 in Clinical Pharmacology & Therapeutics
Verified
Journal Article
Closed access
PDF file
ATA Tornio
A Tornio
AFA M Filppula
A M Filppula
OKO Kailari
O Kailari
MNM Neuvonen
M Neuvonen
TNT H Nyrönen
T H Nyrönen
JBJ T Backman
J T Backman

21 July 2010 in Clinical Pharmacology & Therapeutics
Verified
Journal Article
Closed access
PDF file
TTTuija Tapaninen
Tuija Tapaninen
PNP J Neuvonen
P J Neuvonen
MNM Niemi
M Niemi

30 December 2010 in British Journal of Clinical Pharmacology
Verified
Journal Article
Open access
PDF file
TTTuija Tapaninen
Tuija Tapaninen
PNPertti J. Neuvonen
Pertti J. Neuvonen
MNMikko Niemi
Mikko Niemi
WHAT IS ALREADY KNOWN ABOUT THIS SUBJECT• Aliskiren is an antihypertensive drug with a low oral bioavailability.• Aliskiren is eliminated primarily unchanged into bile, and it is a substrate of the organic anion transporting polypeptide 2B1 (OATP2B1) influx transporter, the P‐glycoprotein efflux transporter and cytochrome P450 3A4.• Flavonoids in orange and apple juice have been shown to inhibit OATP2B1in vitro.WHAT THIS STUDY ADDS• Orange juice and apple juice markedly reduce the plasma concentrations of aliskiren probably by inhibiting its OATP2B1‐mediated intestinal absorption.• Concomitant intake of aliskiren with orange or apple juice is best avoided.AIMThe aim of this study was to investigate the effects of orange juice and apple juice on the pharmacokinetics and pharmacodynamics of aliskiren.METHODSIn a randomized crossover study, 12 healthy volunteers ingested 200 ml of orange juice, apple juice or water three times daily for 5 days. On day 3, they ingested a single 150‐mg dose of aliskiren. Plasma aliskiren concentrations were measured up to 72 h, its excretion into urine up to 12 h and plasma renin activity up to 24 h.RESULTSOrange and apple juice reduced aliskiren peak plasma concentrations by 80% (95% CI 63%, 89%,P< 0.001) and 84% (95% CI 72%, 91%,P< 0.001), and the area under the plasma aliskiren concentration–time curve (AUC) by 62% (95% CI 47%, 72%,P< 0.001) and 63% (95% CI 46%, 74%,P< 0.001), respectively, but had no significant effect on its elimination half‐life or renal clearance. The decreases in aliskiren AUC by orange and apple juice correlated with aliskiren AUC during the water phase (r= 0.98,P< 0.001). Plasma renin activity was 87% and 67% higher at 24 h after aliskiren during the orange juice and apple juice phases, respectively, than during the water phase (P< 0.05).CONCLUSIONSOrange juice and apple juice greatly reduce the plasma concentrations and renin‐inhibiting effect of aliskiren, probably by inhibiting its OATP2B1‐mediated influx in the small intestine. Concomitant intake of aliskiren with orange or apple juice is best avoided.

7 March 2011 in The Journal of Clinical Pharmacology
Verified
Journal Article
Closed access
PDF file
TTTuija Tapaninen
Tuija Tapaninen
JBJanne T. Backman
Janne T. Backman
KKKaisa J. Kurkinen
Kaisa J. Kurkinen
PNPertti J. Neuvonen
Pertti J. Neuvonen
MNMikko Niemi
Mikko Niemi

30 October 2019 in Clinical and Translational Science
Verified
Journal Article
Open access
PDF file
TTTuija Tapaninen
Tuija Tapaninen
AOAleksi M. Olkkola
Aleksi M. Olkkola
ATAleksi Tornio
Aleksi Tornio
MNMikko Neuvonen
Mikko Neuvonen
EEErkki Elonen
Erkki Elonen
JBJanne T. Backman
Janne T. Backman
The oral bioavailability of ibrutinib is low and variable, mainly due to extensive first‐pass metabolism by cytochrome P450 (CYP) 3A4. The unpredictable exposure can compromise its safe and effective dosing. We examined the impact of itraconazole on ibrutinib pharmacokinetics. In a randomized crossover study, 11 healthy subjects were administered itraconazole 200 mg or placebo twice on day 1, and once on days 2–4. On day 3, 1 hour after itraconazole (placebo) and breakfast, ibrutinib (140 mg during placebo; 15 mg during itraconazole) was administered. Itraconazole increased the dose‐adjusted geometric mean area under the concentration‐time curve from zero to infinity (AUC0–∞) of ibrutinib 10.0‐fold (90% confidence interval (CI) 7.2–13.9; P < 0.001) and peak plasma concentration (Cmax) 8.8‐fold (90% CI 6.3–12.1; P < 0.001). During itraconazole, the intersubject variation for the AUC0–∞ (55%) and Cmax (53%) was around half of that during placebo (104%; 99%). In conclusion, itraconazole markedly increases ibrutinib bioavailability and decreases its interindividual variability, offering a possibility to improved dosing accuracy and cost savings.

24 June 2022 in Clinical Pharmacology & Therapeutics
Verified
Journal Article
Open access
AMAnssi J. H. Mykkänen
Anssi J. H. Mykkänen
STSuvi Taskinen
Suvi Taskinen
MNMikko Neuvonen
Mikko Neuvonen
MPMaria Paile‐Hyvärinen
Maria Paile‐Hyvärinen
ETE. Katriina Tarkiainen
E. Katriina Tarkiainen
MNMikko Niemi
Mikko Niemi
We investigated genetic determinants of single‐dose simvastatin pharmacokinetics in a prospective study of 170 subjects and a retrospective cohort of 59 healthy volunteers. In a microarray‐based genomewide association study with the prospective data, the SLCO1B1 c.521T>C (p.Val174Ala, rs4149056) single nucleotide variation showed the strongest, genomewide significant association with the area under the plasma simvastatin acid concentration‐time curve (AUC; P = 6.0 × 10−10). Meta‐analysis with the retrospective cohort strengthened the association (P = 1.6 × 10−17). In a stepwise linear regression candidate gene analysis among all 229 participants, SLCO1B1 c.521T>C (P = 1.9 × 10−13) and CYP3A4 c.664T>C (p.Ser222Pro, rs55785340, CYP3A4*2, P = 0.023) were associated with increased simvastatin acid AUC. Moreover, the SLCO1B1 c.463C>A (p.Pro155Thr, rs11045819, P = 7.2 × 10−6) and c.1929A>C (p.Leu643Phe, rs34671512, P = 5.3 × 10−4) variants associated with decreased simvastatin acid AUC. Based on these results and the literature, we classified the volunteers into genotype‐predicted OATP1B1 and CYP3A4 phenotype groups. Compared with the normal OATP1B1 function group, simvastatin acid AUC was 273% larger in the poor (90% confidence interval (CI), 137%, 488%; P = 3.1 × 10−6), 40% larger in the decreased (90% CI, 8%, 83%; P = 0.036), and 67% smaller in the highly increased function group (90% CI, 46%, 80%; P = 2.4 × 10−4). Intermediate CYP3A4 metabolizers (i.e., heterozygous carriers of either CYP3A4*2 or CYP3A4*22 (rs35599367)), had 87% (90% CI, 39%, 152%, P = 6.4 × 10−4) larger simvastatin acid AUC than normal metabolizers. These data suggest that in addition to no function SLCO1B1 variants, increased function SLCO1B1 variants and reduced function CYP3A4 variants may affect the pharmacokinetics, efficacy, and safety of simvastatin. Care is warranted if simvastatin is prescribed to patients carrying decreased function SLCO1B1 or CYP3A4 alleles.